This study aims to screen 2,100 patients over 3 years with an expectation that 210 will develop severe AKI, 150 will have a urine NGAL >150 ng/ml, 100 patients will develop >10% FO, and 50 of patients will require CRRT. This evidence concerns the gene LCN2 and acute kidney injury.